CORRECTION TO “TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING MICE”

doi:10.1124/dmd.33.1.200

See original article:

TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE - November 01, 2004

In the above article [Xiang H, Nguyen CB, Kelley SK, Dybdal N, and Escandón E (2004) Drug Metab Dispos 32:1230-1238], the wrong Figs. 2, 3, 5, 6, 7, and 10 appeared. The correct figures follow. The online version has been corrected in departure from the print version.

Fig. 2.

Recovery of Apo2L/TRAIL in human serum determined by ELISA and an alamarBlue bioassay. Apo2L/TRAIL at 1 μg/ml, 10 μg/ml, and 25 μg/ml was incubated for 0, 1, 2, 4, 8, 24, and 48 h at 37°C with pooled human serum. A, the percentage of Apo2L/TRAIL recovered from human serum by ELISA was normalized to the control group. B, Apo2L/TRAIL bioactivity at different concentrations and time points was compared with the control group.

Fig. 3.

Concentration versus time profiles for Apo2L/TRAIL. ¹²⁵I-Apo2L/TRAIL serum concentrations were determined by analysis of TCA-precipitable radioactivity at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after administration. Nanogram-equivalents of precipitable ¹²⁵I-Apo2L/TRAIL were calculated and are shown on the y-axis. Apo2L/TRAIL serum concentrations were analyzed by ELISA. Data are from three mice per time point.

We regret any confusion or inconvenience caused by this printing error.

Fig. 5.

Nanogram-equivalents of total ¹²⁵I-Apo2L/TRAIL measured in tissues and tumor. Total radioactivity of ¹²⁵I-Apo2L/TRAIL in kidney, liver, lung, spleen, tumor, and plasma was measured at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after dosing with ¹²⁵I-Apo2L/TRAIL (A) or ¹²⁵I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL (B). Nanogram-equivalents of ¹²⁵I-Apo2L/TRAIL were calculated as described under Materials and Methods and are shown on the y-axis.

Fig. 6.

Total ¹²⁵I-Apo2L/TRAIL in kidney and tumor. Figures represent ¹²⁵IApo2L/TRAIL radioactivity (cpm/g) in kidney (A) and tumor (B) at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after dosing ¹²⁵I-Apo2L/TRAIL or ¹²⁵I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL.

Fig. 7.

Nanogram-equivalents of TCA-precipitable ¹²⁵I-Apo2L/TRAIL in tissues and tumor. TCA-precipitable ¹²⁵I-Apo2L/TRAIL in kidney, liver, lung, spleen, tumor, and plasma were measured at 5 min, 15 min, 30 min, 1 h, 2 h, and 4 h after dosing ¹²⁵I-Apo2L/TRAIL (A) or ¹²⁵I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL (B). Nanogram-equivalents of ¹²⁵I-Apo2L/TRAIL were calculated and are shown on the y-axis.

Fig. 10.

Tissue-to-blood ratios of ¹²⁵I-Apo2L/TRAIL in tissue. Tissue-to-blood ratios of ¹²⁵I-Apo2L/TRAIL in kidney, liver, blood pool, brain, lung, stomach, and intestine at 15 min and 1 h after dosing with ¹²⁵I-Apo2L/TRAIL (A) or ¹²⁵I-Apo2L/TRAIL plus unlabeled Apo2L/TRAIL (B).